CoChat

Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI‐liraglutide study 5)

Open access
Ahmadi, S. S., Filipsson, K., Dimenäs, H., Isaksson, S. S., Imberg, H., Sjöberg, S., Ahrén, B., Dahlqvist, S., Gustafsson, T., Tuomilehto, J., Hirsch, I. B., Lind, M. · 2019 · Obesity Science & Practice
Cited by 14

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Summary: Aim: Use of the glucagon‐like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist‐to‐hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI). Materials and methods: In the multicentre, double‐blind, placebo‐controlled MDI‐liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist‐to‐hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization. Results: Baseline‐adjusted mean weight loss was 3.8 ± 2.9 kg greater in liraglutide than placebo‐treated individuals (p < 0.0001). Waist circumference was reduced by 2.9 ± 4.3 cm and 0.2 ± 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline‐adjusted mean difference: 2.6 ± 4.0 cm, p = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 ± 1.7 cm and 0.0 ± 1.8 cm (baseline‐adjusted mean difference: 1.1 ± 1.7 cm, p = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline‐adjusted mean difference between treatment groups: 2.8 ± 3.8 cm, p = 0.0001), but there was no significant difference between the groups in either waist‐to‐hip ratio (baseline‐adjusted mean difference: 0.0 ± 0.04 cm, p = 0.51) or adiponectin levels (baseline‐adjusted mean difference: 0.8 ± 3.3 mg L−1, p = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter. Conclusions: In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long‐term hyperglycaemia but did not affect adiponectin levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/osp4.324

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 16

  1. International Diabetes Federation, 2017, IDF Diabetes Atlas
  2. 10.1007/s00125-012-2534-0 · DOI · Paper page
  3. 10.2337/dc14-2441 · DOI · Paper page
  4. 10.2337/dci18-0033 · DOI · Paper page
  5. 10.1136/bmjdrc-2017-000464 · DOI · Paper page
  6. Haluzik M, 2005, Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance, Curr Opin Investig Drugs, 6, 988
  7. Esfahani M, 2015, Adiponectin: an adipokine with protective features against metabolic syndrome, Iran J Basic Med Sci, 18, 430
  8. 10.1016/j.pcd.2014.07.010 · DOI
  9. 10.2146/ajhp150990 · DOI · Paper page
  10. 10.1007/s40265-015-0408-8 · DOI
  11. Rondanelli M, 2016, Twenty‐four‐week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus, Patient Prefer Adherence, 10, 407
  12. 10.1590/S0004-27302007000600013 · DOI
  13. 10.1016/j.metabol.2010.04.019 · DOI
  14. 10.2119/molmed.2011.00051 · DOI · Paper page
  15. 10.1016/j.diabres.2015.05.051 · DOI
  16. LindM.Glycaemic control: evaluation of HbA1c as a risk factor and the effect of modern insulins in clinical practicehttp://hdl.handle.net/2077/19641 Accessed May 25 2018.

Cited by

Metadata

Authors
Ahmadi, S. S., Filipsson, K., Dimenäs, H., Isaksson, S. S., Imberg, H., Sjöberg, S., Ahrén, B., Dahlqvist, S., Gustafsson, T., Tuomilehto, J., Hirsch, I. B., & Lind, M.
Venue
Obesity Science & Practice
Publisher
Wiley
Published
2019-03-18
Volume
5
Issue
2
Pages
130-140
ISSN
2055-2238 (ISSN-L)
OpenAlex
W2906141776
Cited by
14
References
13
FWCI
1.19
Type
journal article
Language
en
Open access
gold
Funders
Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.